Dendreon Corp. rose after winning the backing of European Union regulators for the prostate cancer treatment Provenge, the company’s only marketed product.
Sanofi-Aventis SA made a takeover approach to Genzyme Corp. , the largest maker of medicines for genetic diseases, about two weeks ago, said two people with knowledge of the matter.
Dendreon Corp. rose the most in a year on optimism that more patients will begin taking the biotechnology company’s prostate cancer drug Provenge.
Harris Corp. a maker of communications-related electronic equipment, sued Netgear Inc. for allegedly infringing network-security patents.
Amgen Inc., the world’s largest biotechnology company, agreed to buy Micromet Inc. in a $1.16 billion deal to gain an experimental leukemia drug.
Vertex Pharmaceuticals Inc. rose in New York trading after its hepatitis C drug made treatment quicker and more effective in a study that may lead to $1.8 billion in annual U.S. sales.
U.S. stocks were little changed, after the Standard & Poor’s 500 Index rose to a five-year high, as banks slumped and China’s inflation grew. The Chicago Board Options Exchange Volatility Index fell to the lowest since 2007.
Merck & Co. won a U.S. panel’s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.
Vertex Pharmaceuticals Inc. rose 12 percent in intraday trading after U.S. regulators said the company’s experimental hepatitis C drug cures more patients than current therapies.
GlaxoSmithKline Plc and Human Genome Sciences Inc. won a U.S. panel’s backing to sell the first new lupus drug in more than 50 years. Human Genome’s shares jumped 9.5 percent in extended trading.
"We were impressed by the loyalty of active users of Provenge."
- Geoffrey Porges on Jan 11, 2013